Results 111 to 120 of about 86,748 (312)

Effect of Hematopoietic Stem Cell Transplantation Regimen on Tacrolimus Pharmacokinetics

Current Therapeutic Research
: Objectives: Treatment with tacrolimus requires strict control of the whole-blood concentration in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
Haruno Oku, BS, Saki Yoshida, BS, Takumi Hotta, BS, Hirohito Muroi, BS, Keizo Fukushima, PhD, Kei Irie, PhD, Tatsuya Hirano, BS, Yoshimitsu Shimomura, MD, Takayuki Ishikawa, MD, PhD, Hiroaki Ikesue, PhD, Nobuyuki Muroi, PhD, Tohru Hashida, PhD, Nobuyuki Sugioka, PhD   +12 more
doaj   +1 more source

Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies

Haematologica, 2009
Background Cord blood transplant is a feasible treatment alternative for adult patients with hematologic malignancies lacking a suitable HLA-matched donor.
Federico Moscardó, Jaime Sanz, Leonor Senent, Susana Cantero, Javier de la Rubia, Pau Montesinos, Dolores Planelles, Ignacio Lorenzo, Jose Cervera, Javier Palau, Miguel A. Sanz, Guillermo F. Sanz   +11 more
doaj   +1 more source

Steps in immunosuppression for renal transplantation [PDF]

, 1983
The authors provide a historical survey of the immunosuppressive agents that have been used to prevent allograft rejection.
Hakala, TR, Rosenthal, JT, Starzl, TE
core  

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

Protective effect of astaxanthin on myocardial injury induced by autologous liver transplantation in rats in conjunction with the Nrf2/HO-1 pathway

Scientific Reports
This study investigated astaxanthin’s cardioprotective effects in rat autologous orthotopic liver transplantation. Male Wistar rats received astaxanthin (500 mg/kg) for two weeks before transplantation, with controls including sham, transplant-only, and ...
Shujun Lu, Yajing Zhang, Yiqi Weng
doaj   +1 more source

Blinatumomab added to conditioning regimen of allogeneic hematopoietic stem cell transplantation for adult MRD-positive acute lymphoblastic leukemia: a single-center case series

Hematology
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) remains the mainstay of treatment for adults with high-risk acute lymphoblastic leukemia (ALL).
Hui Fu, Yanmin Zhao, Huarui Fu, Meng Liu, Congxiao Zhang, Li Yang, He Huang, Jimin Shi, Jian Yu   +8 more
doaj   +1 more source

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

Haematologica, 2011
Background Allogeneic hematopoietic cell transplantation is a potentially curative treatment for patients with acute lymphoblastic leukemia. However, the majority of older adults with acute lymphoblastic leukemia are not candidates for myeloablative ...
Ron Ram, Rainer Storb, Brenda M. Sandmaier, David G. Maloney, Ann Woolfrey, Mary E. D. Flowers, Michael B. Maris, Ginna G. Laport, Thomas R. Chauncey, Thoralf Lange, Amelia A. Langston, Barry Storer, George E. Georges   +12 more
doaj   +1 more source

Mycophenolate Mofetil Treatment Reduces the Risk of Treatment Escalation Due to Vascular Complications in Limited Cutaneous Systemic Sclerosis: Emulation of a Target Trial From the Italian Rheumatology Society SPRING Registry

Arthritis Care &Research, EarlyView.
Objective Mycophenolate mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon because of the lower fibrotic burden and the predominance of vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function.
Enrico De Lorenzis, Gerlando Natalello, Rossella De Angelis, Lucrezia Verardi, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Silvia Bellando‐Randone, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Maria Ilenia De Andres, Alessandro Giollo, Cosimo Bruni, Martina Orlandi, Marco Fornaro, Marta Saracco, Cecilia Agnes, Pier Giacomo Cerasuolo, Gabriella Alonzi, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria‐Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Fabrizio Conti, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Maria Antonietta D'Agostino, Clodoveo Ferri, Marco Matucci Cerinic, Silvia Laura Bosello, on behalf of the SPRING Italian Registry Collaborators   +77 more
wiley   +1 more source

Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy

Stem Cells and Cloning: Advances and Applications, 2014
Olga Blau, Igor Wolfgang Blau Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders.
Blau O, Blau IW
doaj  

Multiple Myeloma : an update on disease biology and therapy [PDF]

, 2004
Multiple myeloma is a malignancy of immunoglobulin producing plasma cells. Clinical features include bone pain due to lytic bone lesions or pathological fractures, anemia, symptomatic hypercalcemia, renal insufficiency, recurrent infections and ...
Cook, Rachel J., Dingli, David
core